Matt Karlyn has 25 years of experience in working with companies in the healthcare, pharmaceutical, medical device, and technology industries on a wide range of commercial life sciences, licensing, and technology transactions. His clients range from Fortune 100 companies to start-ups, and he regularly advises companies on matters involving IP commercialization, complex collaboration transactions, licensing initiatives, subscription-based economics, and business transactions related to the procurement, development, commercialization, and use of technology and life sciences products. He has also worked with a number of clients on corporate transactions including mergers and acquisitions, as well as private equity and venture capital financing.
Matt is ranked Band 1 by Chambers USA for Intellectual Property: Licensing in Massachusetts. Clients in Chambers describe Matt as: “accessible and engaged, and he is really focused on getting the right answer for us."
Life Sciences
Life sciences clients, including pharmaceutical, medical device, and healthcare companies, rely on Matt for his breadth of knowledge in licensing, collaboration, and commercialization strategies across a wide range of transactions designed to strengthen operations and maximize value. Matt’s clients come from sectors across the global economy and include emerging companies, privately held companies, and many of the world’s biggest brands.
MoFo Life Sciences Blog: Insights and Analyses on Industry TrendsExperience
USD 1.5 billion+ exclusive license agreement between CSPC Pharmaceutical Group Limited and Elevation Oncology, Inc. to supply, develop and commercialize SYSA1801, a clinical stage antibody drug conjugate (ADC) targeting Claudin18.2, in all global territories outside Greater China.
USD 700 million+ exclusive license agreement between CSPC Pharmaceutical Group Limited and Corbus Pharmaceutical Holdings to supply, develop and commercialize SYS6002, a clinical stage antibody drug conjugate (ADC) targeting Nectin-4, in the U.S., Australia, Canada, and varied European countries.
Represented ACEA Therapeutics in an exclusive license agreement with Sorrento Therapeutics to develop and commercialize Abivertinib, a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK).
Represented ACEA Therapeutics in USD 488 million merger and acquisition transaction by their licensee, Sorrento Therapeutics.
Represented Kindred Biosciences in an exclusive license agreement with Elanco Animal Health Incorporated to globally develop and commercializeKIND-030, a monoclonal antibody targeting canine parvovirus (CPV).
Represented Kindred Biosciences, Inc. in USD 440 million acquisition transaction by their licensee, Elanco US, Inc.
Represented Sanuwave Health in a license and marketing agreement with Celularity Inc. to commercialize BIOVANCE® Human Amniotic Membrane Allograft and Interfyl® Human Connective Tissue Matrix.
Represented MyChem, a privately held provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets, in connection with its ≈ USD 240 million sale to Maravai (NASDAQ: MRVI).
Represented Special New Fruit Licensing (SNFL) in its acquisition of International Fruit Genetics (IFG).
Represented Sequlite Genomics, a company that focuses on developing Next-Generation Sequencing (NGS) technology, in connection with its sale to Fapon Biotech.